A Study Evaluating Escalating Doses of 131I-BC8 (Anti-CD45) Antibody Followed by Autologous Stem Cell Transplantation for Relapsed or Refractory Lymphoid Malignancies
Latest Information Update: 07 Apr 2022
At a glance
- Drugs I-131-Apamistamab (Primary)
- Indications B-cell lymphoma; Hodgkin's disease; Mantle-cell lymphoma; T-cell lymphoma
- Focus Adverse reactions; Therapeutic Use
- 26 Mar 2020 Status changed from active, no longer recruiting to discontinued.
- 29 Aug 2019 Planned End Date changed from 30 Oct 2017 to 21 Mar 2020.
- 19 May 2016 Status changed from recruiting to active, no longer recruiting.